Comparison of the radiolabeled PSMA-inhibitor 111In-PSMA-617 and the radiolabeled GRP-R antagonist 111In-RM2 in primary prostate cancer samples

Purpose Prostate-specific membrane antigen (PSMA) and gastrin-releasing peptide receptor (GRP-R) are expressed in prostate cancer and can be targeted with radiolabeled inhibitors and antagonists. Their performances for the initial characterization of prostatic tumors have been barely evaluated but n...

Full description

Saved in:
Bibliographic Details
Published in:EJNMMI research Vol. 9; no. 1; pp. 1 - 7
Main Authors: Schollhammer, Romain, De Clermont Gallerande, Henri, Yacoub, Mokrane, Quintyn Ranty, Marie-Laure, Barthe, Nicole, Vimont, Delphine, Hindié, Elif, Fernandez, Philippe, Morgat, Clément
Format: Journal Article
Language:English
Published: Berlin/Heidelberg Springer Berlin Heidelberg 03.06.2019
Springer Nature B.V
SpringerOpen
Subjects:
Antigens
Binding
Cancer surgery
Cardiac Imaging
GRP-R
Histology
Imaging
Inhibitors
Medicine
Medicine & Public Health
Metastasis
Nuclear Medicine
Oncology
Original Research
Orthopedics
Prostate cancer
PSMA
Radiology
Tracers
Tumors
GRP-R
Prostate cancer
PSMA
ISSN:2191-219X, 2191-219X
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose Prostate-specific membrane antigen (PSMA) and gastrin-releasing peptide receptor (GRP-R) are expressed in prostate cancer and can be targeted with radiolabeled inhibitors and antagonists. Their performances for the initial characterization of prostatic tumors have been barely evaluated but never compared. We aimed to gather comparative preclinical data of the role of PSMA and GRP-R targeting in prostate cancer. Procedures We retrospectively studied 20 frozen prostatectomy samples with various metastatic risks of the D’Amico classification. Tissue samples were investigated by tissular microimaging using the radiolabeled PSMA inhibitor 111 In-PSMA-617 and the radiolabeled GRP-R antagonist 111 In-RM2. Bindings of the two radiopharmaceuticals were compared to histology and clinico-biological data (Gleason score, PSA values, metastatic risks). Results Binding of 111 In-PSMA-617 was high whatever the metastatic risk ( p  = 0.665), Gleason score ( p  = 0.555), or PSA value ( p  = 0.404) while 111 In-RM2 exhibited a significantly higher binding in the low metastatic risk group ( p  = 0.046), in the low PSA value group ( p  = 0.001), and in samples with Gleason 6 score ( p  = 0.006). Conclusion PSMA and GRP-R based imaging might have complementary performances for the initial characterization of prostatic tumors. Prospective clinical studies comparing the two tracers in this setting are needed.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:2191-219X
2191-219X
DOI:10.1186/s13550-019-0517-6